Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Oral anticoagulants (OACs) are crucial for preventing stroke in atrial fibrillation (AF).
• Despite the availability of direct oral anticoagulants (DOACs), OAC treatment in AF patients remains suboptimal.
• Real-world data analysis is essential to understand current treatment trends and guideline implementation.

Purpose of the Study:

• To assess temporal trends in OAC treatment rates for atrial fibrillation (AF) patients.
• To evaluate the current implementation of OAC treatment guidelines in real-world settings.
• To identify predictors associated with OAC initiation in AF patients.

Main Methods:

• Retrospective cohort study utilizing data from Clalit Health Services in Israel (2014-2019).
• Inclusion of adult patients with newly diagnosed nonvalvular AF and CHA₂DS₂-VASc score ≥2.
• Calculation of OAC treatment rates and application of multivariate regression models to identify predictors.

Main Results:

• A significant increase in 3-month OAC treatment rates was observed from 46.9% (2014-2015) to 61.7% (2018-2019).
• DOACs rapidly became the dominant OAC, increasing from 51.3% to 95.1% during the study period.
• Predictors of OAC initiation included higher CHA₂DS₂-VASc score, higher socioeconomic class, female sex, Jewish ethnicity, statin use, and prior colorectal cancer screening; lower likelihood was seen in smokers and those with renal impairment.

Conclusions:

• While OAC treatment rates in high-risk AF patients are increasing, primarily due to DOAC adoption, they have not yet reached optimal levels.
• Continued efforts are needed to improve OAC guideline adherence and ensure adequate stroke prevention in AF.
• Understanding patient and system-level factors influencing OAC initiation is key to optimizing treatment strategies.